Breast Cancer Margin Threshold Should Not Be Applied Beyond the Population Studied
A proposed 1 mm tumour-free margin after breast-conserving surgery has already begun to look attractive because it offers a crisp surgical rule. The problem is that surgical oncology rarely behaves neatly enough for a single threshold to travel intact across different treatment pathways. In this BMJ rapid response, the central warning is straightforward: the evidence behind the 1 mm cut-off comes from a very specific group, and moving it into other clinical settings risks overreading the data.
The underlying meta-analysis linked close margins with higher risks of local recurrence, distant recurrence and mortality in early-stage invasive breast cancer. That finding challenges the older “no tumour on ink” standard and raises the possibility that microscopic residual disease still matters biologically even when the inked edge is technically negative. Yet the practical meaning of that association depends heavily on who underwent surgery, what treatment came before the operation, and which disease subtype is under discussion. Margin status is not just a pathology label; it is a proxy for how far invasive cells may extend beyond what the surgeon can see and what the pathologist can sample.
One sentence captures the danger plainly: a 1 mm rule for upfront surgery is not automatically a 1 mm rule for everyone.
Neoadjuvant Therapy Changes the Meaning of a Margin
Patients who received neoadjuvant chemotherapy were excluded from the meta-analysis, and that exclusion is not a minor technical detail. Preoperative systemic therapy can shrink tumors dramatically, fragment the original disease footprint, and leave behind scattered nests of viable cells within a field of treatment effect. In that setting, the distance between the final excision edge and the residual tumor does not mean the same thing it means in untreated primary surgery. Pathologic response after neoadjuvant therapy also introduces a different biological question: is the surgeon measuring the extent of the original tumor, or the remnant of a lesion already altered by systemic treatment?
For that reason, extrapolating the 1 mm threshold to neoadjuvant-treated patients would be speculative. The concern is not theoretical. Breast conservation after preoperative therapy has become common, and this subgroup is large enough that a margin rule built only from primary-surgery cases could distort daily decision-making. Surgeons may feel pressure to re-excise tissue that is already adequately treated, or, in the opposite direction, may rely on a margin cut-off that underestimates the complexity of residual disease distribution after therapy. Neither outcome serves patients well.
Close Margins Are Heterogeneous, Not a Single Biological State
The comment also points to another weakness in the evidence base: the definition of “close margin” varied across the observational studies pooled in the meta-analysis. In practice, one study’s close margin may not match another’s, which makes the combined estimate less tidy than a guideline-style recommendation might imply. Aggregate study-level meta-analysis is useful for identifying broad patterns, but it cannot fully resolve heterogeneity in pathology technique, radiotherapy use, re-excision policies, or tumor biology.
This matters because margin width is shaped by more than a millimeter ruler. Tumor grade, multifocality, lymphovascular invasion, molecular subtype, and the use of boost radiotherapy all influence locoregional control. Even the decision to re-excise can become part of the causal chain: patients with smaller margins are more likely to undergo additional surgery, which may itself alter downstream recurrence risk and obscure the original effect of the first operation. Observational data can show association, but it cannot cleanly separate surgical margin width from the biologic aggressiveness that often travels with it.
DCIS Remains a Different Disease With a Different Margin Standard
The response also draws a hard line between invasive breast cancer and ductal carcinoma in situ (DCIS). The pooled analysis was restricted to invasive disease and should not be casually imported into the in-situ setting, where existing guidance commonly uses a 2 mm threshold. DCIS behaves differently at the histologic and clinical level, with distinct patterns of ductal spread and local recurrence risk. A margin standard that may be defensible for invasive carcinoma cannot be assumed to hold for in-situ lesions simply because both arise in the breast.
That separation is clinically important because margin discussions often drift toward simplification. A number can be seductive. It can make multidisciplinary planning feel more decisive than the underlying evidence permits. Yet the biologic differences between invasive cancer and DCIS justify different thresholds, different surgical tolerances, and different expectations for local control.
Individual-Patient Data Could Clarify Who Really Benefits
An individual-patient-data meta-analysis would be the right tool to move this field forward. Study-level pooling cannot fully standardize how margins are measured, cannot reliably stratify primary surgery against neoadjuvant settings, and cannot separate invasive disease from DCIS with enough precision to guide nuanced practice. Patient-level data would also allow stronger adjustment for confounders such as radiotherapy boost, tumor subtype, and the choice to re-excise after an initial close margin.
Such work could answer a more clinically useful question than the current pooled estimate does: in which patients does a slightly wider margin actually change recurrence risk enough to justify additional tissue removal? Without that granularity, a 1 mm threshold risks becoming a blunt instrument. Surgeons need rules they can apply at the bedside, but those rules have to survive contact with pathology, oncology, and the biology of treated tissue.
Margin Status Still Deserves Careful Reporting, Not Automatic Universalization
The strongest message here is not that margin status is unimportant. It is the opposite. Margin assessment remains central to breast conservation, and careful pathological reporting should continue to improve. But the proposed 1 mm threshold belongs to patients who underwent upfront primary breast-conserving surgery, not to every patient with breast cancer who reaches the operating room by a different route.
The evidence base is already specific enough to justify caution and narrow enough to resist overgeneralization. Before a new cut-off is written into routine practice, clinicians need data from neoadjuvant-treated patients, clearer separation of invasive disease from DCIS, and better control of the clinical factors that shape recurrence risk independently of margin width. Until then, the safest interpretation is also the most disciplined one: the margin threshold is informative, but only within the population from which it was derived.